Foghorn Therapeutics (FHTX) shares rallied significantly after announcing robust second-quarter financial results and promising updates on its oncology pipeline. However, despite the recent jump, analysts remain cautious due to a negative trend in earnings estimate revisions.
Foghorn Therapeutics (FHTX) stock has seen a significant rise in recent weeks, and Wall Street analysts are predicting even more growth. While analysts’ price targets can be misleading, a strong consensus and positive earnings revisions suggest FHTX could be poised for further gains.
